Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marialuisa Moccia

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Advances in Experimental Medicine and Biology|July 2, 2025
Iron and Cell DeathGiorgia Federico, Marialuisa Moccia, Francesca Carlomagno
Endocrine-Related Cancer|October 16, 2024
Mechanisms of RET-mediated signal transductionFrancesca Carlomagno, Marialuisa Moccia, Giorgia Federico, et al.
Genes|April 25, 2020
RET Gene Fusions in Malignancies of the Thyroid and Other TissuesMassimo Santoro, Marialuisa Moccia, Giorgia Federico, et al.
European Journal of Medicinal Chemistry|September 19, 2014
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluationBrendan Frett, Marialuisa Moccia, Francesca Carlomagno, et al.
Scientific Reports|November 25, 2025
Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteinsMarialuisa Moccia, Lingzhi Zhang, Zhengyu Wang, et al.
European Journal of Medicinal Chemistry|March 2, 2021
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluationWei Yan, Lingtian Zhang, Fengping Lv, et al.
Scientific Reports|May 23, 2025
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STINGGiorgia Federico, Angelo Rosario Carotenuto, Arsenio Cutolo, et al.
JCO Precision Oncology|August 3, 2023
D898_E901 <i>RET</i> Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent MechanismsTommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano, et al.
Scientific Reports|August 10, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinasesMarialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, et al.
Journal of Medicinal Chemistry|April 17, 2020
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent PolypharmacologyMarialuisa Moccia, Brendan Frett, Lingtian Zhang, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|July 2, 2025
Iron and Cell DeathGiorgia Federico, Marialuisa Moccia, Francesca Carlomagno
Endocrine-Related Cancer|October 16, 2024
Mechanisms of RET-mediated signal transductionFrancesca Carlomagno, Marialuisa Moccia, Giorgia Federico, et al.
Genes|April 25, 2020
RET Gene Fusions in Malignancies of the Thyroid and Other TissuesMassimo Santoro, Marialuisa Moccia, Giorgia Federico, et al.
European Journal of Medicinal Chemistry|September 19, 2014
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluationBrendan Frett, Marialuisa Moccia, Francesca Carlomagno, et al.
Scientific Reports|November 25, 2025
Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteinsMarialuisa Moccia, Lingzhi Zhang, Zhengyu Wang, et al.
European Journal of Medicinal Chemistry|March 2, 2021
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluationWei Yan, Lingtian Zhang, Fengping Lv, et al.
Scientific Reports|May 23, 2025
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STINGGiorgia Federico, Angelo Rosario Carotenuto, Arsenio Cutolo, et al.
JCO Precision Oncology|August 3, 2023
D898_E901 <i>RET</i> Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent MechanismsTommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano, et al.
Scientific Reports|August 10, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinasesMarialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, et al.
Journal of Medicinal Chemistry|April 17, 2020
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent PolypharmacologyMarialuisa Moccia, Brendan Frett, Lingtian Zhang, et al.
Pageof 2